# Dendritic Cell Vaccination for Patients with Solid Tumors

> **NCT01291420** · PHASE1,PHASE2 · COMPLETED · sponsor: **University Hospital, Antwerp** · enrollment: 48 (actual)

## Conditions studied

- Glioblastoma
- Renal Cell Carcinoma
- Sarcomas
- Breast Cancers
- Malignant Mesothelioma
- Colorectal Tumors

## Interventions

- **BIOLOGICAL:** autologous dendritic cell vaccination

## Key facts

- **NCT ID:** NCT01291420
- **Lead sponsor:** University Hospital, Antwerp
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05-03
- **Primary completion:** 2016-04-25
- **Final completion:** 2017-11-02
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2024-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01291420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01291420, "Dendritic Cell Vaccination for Patients with Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01291420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*